CMHX008, a PPARγ partial agonist, enhances insulin sensitivity with minor influences on bone loss
Traditional thiazolidinediones (TZDs), such as rosiglitazone, are peroxisome proliferator-activated receptor γ (PPARγ) potent agonists that can be used to treat type 2 diabetes but carry unwanted effects, including increased risk for fracture. The present work aimed to compare the insulin-sensitizin...
Main Authors: | Yi Hou, Xuemei Cao, Xiangnan Hu, Xinyu Li, Xiaoqin Shi, Hongying Wang, Chuan Peng, Jiayu Li, Jibin Li, Qifu Li, Chaodong Wu, Xiaoqiu Xiao |
---|---|
Format: | Article |
Language: | English |
Published: |
KeAi Communications Co., Ltd.
2018-09-01
|
Series: | Genes and Diseases |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352304218300655 |
Similar Items
-
PPARγ Agonists: Emergent Therapy in Endometriosis
by: Alexandre Vallée, et al.
Published: (2021-06-01) -
Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
by: Nordsletten Lars, et al.
Published: (2009-03-01) -
Structural Basis for PPARs Activation by The Dual PPARα/γ Agonist Sanguinarine: A Unique Mode of Ligand Recognition
by: Siyu Tian, et al.
Published: (2021-10-01) -
Regulation of Neuroinflammatory Signaling by PPARγ Agonist in Mouse Model of Diabetes
by: Iwona Piątkowska-Chmiel, et al.
Published: (2022-05-01) -
Obesity and the microbiome in atopic dermatitis: Therapeutic implications for PPAR-γ agonists
by: Jeremy P. McAleer
Published: (2023-03-01)